Category Archives: Histogen

Updates from the 2015 WCHR and Related News

The 9th World Congress for Hair Research just ended in Miami and there is a surprising lack of online publicly available information regarding key developments. Some companies often publish their presentations on their websites several days after the end of such conferences, so I will update this post in the next week as new information comes out.

2015 Word Congress for Hair Research (WCHR) Updates

Update: 9th World Conference for Hair Research abstracts now available online.

Update: Below is the unbelievable before and after image from Histogen’s Dr. Gail Naughton’s presentation that everyone is talking about (Edit: Image was later removed from source site).

Update: Hellouser’s Youtube channel.

Update: Spencer Kobren’s interview with Histogen’s Dr. Gail Naughton, including all her slides. Very encouraging and an absolute must see.

Update: Spencer Kobren’s interview with Replicel’s Lee Buckler.

— The best place to get updates remains Hellouser’s thread on the HLT forums. He is apparently back in Canada and fatigued at present, but will slowly update that thread (or perhaps create new threads on different companies in that portion of the HLT forums). He is going to load his audio files somewhere outside the forums too.

Samumed came out yet another press release today, summarizing its presentation at the Miami Congress. I am getting more optimistic about the company’s unique SM04554 topical product that tackles hair loss via the Wnt pathway. At present, the company has only concluded that the product is very safe based on its recently completed 300 person trial (interestingly, one of the co-organizers of the 2015 WCHR, Dr. WIlma Bergfeld, was involved in this trial via the Cleveland center).

Actual data on new hair growth will come out as it becomes available, which I am hoping will be in early 2016. The conclusion of the press release is encouraging, even if not pertaining to humans: “SM04554 has been shown to generate new hair follicles and increase hair count in multiple animal models.” At the same time, we have to be wary from past experiences that all these press releases could very well be just a means to attract publicity and funding. The final product could at best always end up being no better than Rogaine.

— I am disappointed that the 2015 WCHR Twitter account has been completely silent during and after the Congress. It is unlikely that they will publish anything this week either, but maybe it is still worth keeping an eye on that account before it ends in Twitter purgatory. Maybe “Helllouser” should get the wwww.twitter.com/2016WCHR account now while no-one has it and then tell the Japanese organizers of next year’s Congress that he will do a much better job of updating it?

— I discussed Allergan twice in this blog recently (see here and here) and it seems like the company is now definitely merging with Pfizer. Together, the new entity will be by far the world’s largest pharmaceutical company. Too early to tell how if at all this will impact the release of Allergan’s Bimatoprost and Setipiprant drugs to treat hair loss.

— Replicel usually publishes its latest presentation on its website and announces them via its Twitter account.

— Histogen remains the big mystery. A few months ago, most people had given up on it. Then things changed and I wrote this post. Now “Hellouser” is saying that he was very impressed with their presentation. I am really looking forward to his interview with CEO Gail Naughton.

Histogen and Replicel Updates

Declining Recent Interest in Histogen and Replicel

Several years ago, the two companies that hair loss sufferers cared about the most were Histogen and Replicel. Over time, news releases from Histogen slowed down and their published results were not especially impressive to the casual observer. While Replicel has remained highly active when it comes to news releases (probably more so than any other company ever involved in the hair loss cure world) and especially responsive on social media platforms, several delays in the company’s clinical trials have turned off many people.  Moreover, just as with Histogen, it is not yet entirely clear as to how great Replicel’s results will be.  It is assumed that once they use many injections, results will be significantly superior to what they have already shown in initial trials involving a limited number of injections.  When it comes to Replicel, making things even less clear is the fact that Replicel’s much larger Japanese partner Shiseido is supplementing Replicel’s technology with its own technology.  Below is an instructive chart showing Google Trends search results for keywords “Histogen” and  “Replicel” since the start of 2008.  Histogen is in red and Replicel is in blue, with the former causing the most excitement in 2010 and the latter in 2012.

Histogen Awakens from its Slumber

After not hearing much about Histogen in the past year, it was a pleasant surprise for me to learn that Histogen and its CEO Gail Naughton will be presenting at the upcoming 9th World Congress for Hair Research in Miami, Florida in November, 2015.  I will be covering the details of this Congress in more detail in the coming weeks.  See the news page on Histogen’s website that describes Dr. Naughton’s upcoming presentation.

Moreover, several months ago Histogen successfully garnered around $10 million in new financing that I mentioned in my brief items of interest post on this blog in July 2015.  Also of interest, Histogen published a new promo video on youtube about 3 months ago that I only saw recently:

Replicel Keeps Presenting and Tweeting Regularly

It seems like Replicel has continued to come out with new presentations virtually every 2 months during the past several years.  The latest from this month can be read here as well as seen in the video below.  That video is from a presentation by Lee Buckler at this month’s Alliance for Regenerative Medicine (ARM)’s annual “Stem Cell Meeting on the Mesa” conference in San Diego, California.  It is worth watching most of the video’s on ARM’s youtube channel.  In the past, both Histogen and Replicel have presented at this annual conference, but this year it was only the latter.

Finally, for those who have questions related to Replicel, you should contact them directly via Twitter or Facebook as they are very responsive.